Md. biopharm gets 2 new neurodegenerative disorder treatment patents
Daily Record Staff//September 7, 2017//

Neuralstem Inc., a Germantown biopharmaceutical company working on treatments for nervous system diseases, was awarded two patents by the U.S. Patent and Trademark Office.
One patent covers ways of treating neurodegenerative disorders through transplantation of neural stem cells. The other covers neural stem cells engineered to express IGF-1, a molecule with potential in the treatment of neurodegenerative disorders.
Rich Daly, chairman and CEO of Neuralstem, said the patents provide additional protection for its platform.
Related Content
Editors Picks
Learn about the 2026 Leaders in Law honorees
21/4/2026
Contractor, MD consultant charged in alleged USPS bribery conspiracy
20/4/2026
Lawyer didn’t commit ‘obvious error’ on cell tower testimony, [...]
20/4/2026
MD colleges start programs to give high schoolers jump on campus life
20/4/2026
Judge: Baltimore IG’s records access ‘crushed’ by administrati[...]
17/4/2026
More News
Judge blocks Trump administration actions stymieing wind, solar projects
21/4/2026
Chavez-DeRemer steps down as US labor secretary amid misconduct probe
21/4/2026
Federal judge blocks $6B Nexstar-Tegna TV merger
21/4/2026
Supreme Court rejects Massachusetts school gender-identity policy challenge
20/4/2026
Trump ballroom construction allowed for now, appeals court says
20/4/2026











